

**Table 1 Appendix Baseline Characteristics in the Analyzed Cohort Expressed as a Function of CAN**

Characteristic	CAN1			CAN2			CAN3		
	No (N=7563)	Yes (N=572)	P-value	No (N=7853)	Yes (N=282)	P-value	No (N=7994)	Yes (N=141)	P-value
Age (years)	61.9 (6.7)	62.5 (6.7)	0.05	62 (6.7)	61.8 (6.5)	0.66	62 (6.7)	62.5 (6.7)	0.33
% Women	39.1	49.7	<0.0001	39.3	55	<0.0001	39.6	51.8	<0.01
% Minorities	36.1	31.8	0.04	35.8	34.4	0.62	35.9	29.1	0.09
% Prior CVD	33.7	41.8	<0.0001	34.3	34	0.93	34.3	33.3	0.81
Diabetes Duration (years)	10.7 (7.6)	12 (8.2)	<0.0001	10.8 (7.7)	10.8 (7.6)	0.88	10.7 (7.7)	12.5 (8)	<0.01
HbA1c (%)	8.3 (1)	8.5 (1.2)	<0.0001	8.3 (1)	8.5 (1.2)	<0.001	8.3 (1.1)	8.6 (1.1)	<0.0001
BMI (kg/m <sup>2</sup> )	32.2 (5.4)	32.8 (5.4)	<0.01	32.2 (5.4)	33.2 (5.5)	<0.01	32.2 (5.4)	34.4 (5.3)	<0.0001
SBP (mm Hg)	136.1 (17)	137.6 (17.3)	0.04	136.2 (17)	137.8 (17)	0.13	136.2 (17)	137.4 (18.5)	0.42
DBP (mm Hg)	74.9 (10.5)	76 (10.9)	0.01	74.8 (10.5)	78.9 (10.8)	<0.0001	74.9 (10.5)	78.3 (11.4)	<0.001
% Peripheral Neuropathy	41.8	49	<0.001	42	50	<0.01	41.3	100	<0.0001
Urinary Albumin/Creatinine (mg/g)	89.5 (358.6)	135 (343.1)	<0.01	91.3 (357.9)	132.3 (349)	0.06	92 (358.9)	133.9 (272.8)	0.17
LDLc (mg/dl)	105.2 (33.8)	104 (34.4)	0.44	105 (33.8)	108.8 (36.5)	0.06	105 (33.9)	107.8 (34.6)	0.33
Triglycerides (mg/dl)	191.3 (151.4)	208.5 (166)	<0.01	191.3 (151.6)	224.1 (174.7)	<0.001	191.8 (152.1)	230.3 (173.2)	<0.01
% Insulin Users	33.6	46.7	<0.0001	34.1	46.5	<0.0001	34.3	50.4	<0.0001
% TZD Users	19.6	19.2	0.84	19.7	16	0.12	19.7	12.1	0.02
% Beta-Blocker Users	28.2	33.2	<0.01	28.8	20.9	<0.01	28.7	17.7	<0.01
% Ace Inhibitor Users	52.7	53.3	0.78	52.9	49.3	0.24	52.8	48.2	0.28
% Statin Users	62.1	62.9	0.68	62.3	56.4	0.04	62.3	53.2	0.03
Alcohol (drinks/week)	1 (2.9)	1.1 (4)	0.53	1 (3)	0.8 (3.4)	0.32	1 (3)	0.7 (2.2)	0.23
% Current Smokers	13.7	15.2	0.32	13.6	19.5	<0.01	13.6	24.8	<0.001
% Former Smokers	43.8	42.7	0.61	44	36.2	<0.01	43.9	34	0.02

Values shown are percentages for dichotomous variables and means (standard deviations) for continuous measures.

HbA1c: hemoglobin A1c, BMI: body mass index, SBP: systolic blood pressure, DPB: diastolic blood pressure, DPN: diabetic peripheral neuropathy diagnosed by any pedal amputation or score > 2 on the Michigan Neuropathy Screening Instrument, LDLc: low density lipoprotein cholesterol, ACEIs: angiotensin converting enzyme inhibitors, ARBs: angiotensin receptor blockers, TZD: thiazolidinediones.

Figure A1

# Participants Analyzed





Figure A2 Associations between CAN and All-Cause Mortality.



**Legend:** Plots present rates and 95% Poisson Confidence Intervals; CAN1 was defined as the lowest quartile of SDNN and the highest quartile of QTI; CAN2 as the lowest quartile of SDNN, the highest quartile of QTI and the highest quartile of heart rate; CAN3 as the lowest quartile of SDNN and , the highest quartiles of QTI and heart rate, in the presence of DPN.